FIV vaccine
OwnerJames Charles Neil, Mark Alan Rigby +1inventors
InventorsJames Charles Neil, Mark Alan Rigby, James Oswald Jarrett
Life of this patent
Estimating the term…
Abstract
Vaccine formulations for FIV related disease comprising a FIPV polynucleotide comprising a dysfunctional pol gene, FIPV polynucleotide fragments, and uses therefor in the prophylaxis and/or treatment of FIV-related diseases.
Claims27
A vaccine formulation comprising a FIPV polynucleotide comprising a dysfunctional pol gene which is substantially incapable of encoding a functionally competent RT or a functional RT fragment thereof.
A formulation according to any one of the preceding claims further comprising a polynucleotide fragment encoding a cytokine.
A formulation according to any one of the preceding claims wherein the FIPV polynucleotide is in naked form.
A formulation according to any preceding claim further comprising an adjuvant.
A FIPV polynucleotide fragment which is substantially incapable of encoding a functional RT or a functional RT fragment thereof for use as a medicament for FIV-related disease.
A FIPV polynucleotide fragment comprising a deletion within the RT domain of the pol gene for use as a medicament for FIV-related disease.
A FIPV polynucleotide fragment comprising an in-frame deletion within the RT domain of the pol gene for use as a medicament for FIV-related disease.
Use of a FIPV comprising a dysfunctional pol gene in the manufacture of a vaccine for the prophylaxis and/or therapy of FIV-related disease.
A method of vaccinating against FIV-related disease in a mammal which comprises administering to the mammal an effective, non-toxic amount of a vaccine formulation according to any one of claims 1-12 or a polynucleotide fragment according to any one of claims 24-26.
A FIPV polynucleotide fragment comprising an in-frame deletion and/or insertion therein in the RT region of the RT domain of the pol gene.
Dependencies are inferred from the claim text.